Nombre del producto:4-(Trifluoromethyl)aniline

IUPAC Name:4-(trifluoromethyl)aniline

CAS:455-14-1
Fórmula molecular:C7H6F3N
Pureza:95%+
Número de catálogo:CM253041
Peso molecular:161.13

Unidad de embalaje Stock disponible Precio($) Cantidad
CM253041-1000g in stock Ʀț

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :455-14-1
Fórmula molecular:C7H6F3N
Punto de fusión:-
Código de sonrisas:C1=C(C(F)(F)F)C=CC(=C1)N
Densidad:
Número de catálogo:CM253041
Peso molecular:161.13
Punto de ebullición:190°C at 760 mmHg
Nº Mdl:MFCD00064396
Almacenamiento:Keep in a tight container and store at ambient temperature

Category Infos

Benzenes
Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

Column Infos

Obicetrapib
The elevated low-density lipoprotein cholesterol (LDL-C) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD), and heterozygous familial hypercholesterolemia (HeFH). Cholesteryl ester transfer protein (CETP) transports cholesterol from good high-density lipoprotein cholesterol (HDL-C) to low-density lipoprotein cholesterol (LDL-C). NewAmsterdam’s Obicetrapib is a novel, selective CETP inhibitor to address the limitations of current treatments.
Obicetrapib is under investigation in phase III clinical trials as a monotherapy product, and in phase II studies as a fixed dose combination with Ezetimibe.